# Jianming Xu

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/jianming-xu-3/

## Facts

| Field | Value |
| --- | --- |
| Citations | 28,469 |
| Field | Gastric Cancer Management and Outcomes |
| h-index | 59 |
| i10-index | 153 |
| Last Known Institution | University of Technology Sydney |
| OpenAlex ID | https://openalex.org/A5100726667 |
| ORCID iD | https://orcid.org/0000-0003-4467-6021 |
| Works | 398 |

## Researcher papers

Showing 12 of 13.

- [Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study](https://scholariq.org/papers/sintilimab-plus-a-bevacizumab-biosimilar-ibi305-versus-sorafenib-in-unresectable/)
- [Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction](https://scholariq.org/papers/randomized-double-blind-placebo-controlled-phase-iii-trial-of-apatinib-in/)
- [Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition)](https://scholariq.org/papers/guidelines-for-the-diagnosis-and-treatment-of-hepatocellular-carcinoma-2019/)
- [Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/regorafenib-plus-best-supportive-care-versus-placebo-plus-best-supportive-care/)
- [Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study](https://scholariq.org/papers/brivanib-versus-sorafenib-as-first-line-therapy-in-patients-with-unresectable/)
- [The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer](https://scholariq.org/papers/the-keynote-811-trial-of-dual-pd-1-and-her2-blockade-in-her2-positive-gastric/)
- [Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of <i>HER2</i>-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN—A Randomized, Phase III Study](https://scholariq.org/papers/lapatinib-plus-paclitaxel-versus-paclitaxel-alone-in-the-second-line-treatment/)
- [Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study](https://scholariq.org/papers/camrelizumab-versus-investigator-s-choice-of-chemotherapy-as-second-line-therapy/)
- [Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma](https://scholariq.org/papers/nivolumab-combination-therapy-in-advanced-esophageal-squamous-cell-carcinoma/)
- [Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition)](https://scholariq.org/papers/guidelines-for-the-diagnosis-and-treatment-of-primary-liver-cancer-2022-edition/)
- [Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer](https://scholariq.org/papers/sintilimab-plus-chemotherapy-for-unresectable-gastric-or-gastroesophageal/)
- [Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study](https://scholariq.org/papers/tislelizumab-plus-chemotherapy-versus-placebo-plus-chemotherapy-as-first-line/)

## Researcher topics

- [Gastric Cancer Management and Outcomes](https://scholariq.org/topics/gastric-cancer-management-and-outcomes/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Esophageal Cancer Research and Treatment](https://scholariq.org/topics/esophageal-cancer-research-and-treatment/)
- [Hepatocellular Carcinoma Treatment and Prognosis](https://scholariq.org/topics/hepatocellular-carcinoma-treatment-and-prognosis/)

## Researcher university

- [University of Technology Sydney](https://scholariq.org/institutions/university-of-technology-sydney/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.